Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression

David R. Bangsberg

doi:10.1086/507526

Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression

David R. Bangsberg

Research output: Contribution to journal › Article › peer-review

450 Scopus citations

Abstract

For antiretroviral therapy, the 95% adherence "threshold" is based on nucloside-exposed patients who are receiving partially suppressive, unboosted protease inhibitor regimens. Using unannounced pill counts and electronic medication monitoring, viral suppression is common with a 54%-100% mean adherence level to nonnucleoside reverse-transcriptase-inhibitor regimens. Although perfect adherence is an important goal, viral suppression is possible with moderate adherence to potent regimens.

Original language	English (US)
Pages (from-to)	939-941
Number of pages	3
Journal	Clinical Infectious Diseases
Volume	43
Issue number	7
DOIs	https://doi.org/10.1086/507526
State	Published - Oct 1 2006
Externally published	Yes

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1086/507526

Cite this

@article{ca9702c916f947e880e51eca37bf9bff,

title = "Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression",

abstract = "For antiretroviral therapy, the 95% adherence {"}threshold{"} is based on nucloside-exposed patients who are receiving partially suppressive, unboosted protease inhibitor regimens. Using unannounced pill counts and electronic medication monitoring, viral suppression is common with a 54%-100% mean adherence level to nonnucleoside reverse-transcriptase-inhibitor regimens. Although perfect adherence is an important goal, viral suppression is possible with moderate adherence to potent regimens.",

author = "Bangsberg, {David R.}",

year = "2006",

month = oct,

day = "1",

doi = "10.1086/507526",

language = "English (US)",

volume = "43",

pages = "939--941",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "7",

}

TY - JOUR

T1 - Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression

AU - Bangsberg, David R.

PY - 2006/10/1

Y1 - 2006/10/1

N2 - For antiretroviral therapy, the 95% adherence "threshold" is based on nucloside-exposed patients who are receiving partially suppressive, unboosted protease inhibitor regimens. Using unannounced pill counts and electronic medication monitoring, viral suppression is common with a 54%-100% mean adherence level to nonnucleoside reverse-transcriptase-inhibitor regimens. Although perfect adherence is an important goal, viral suppression is possible with moderate adherence to potent regimens.

AB - For antiretroviral therapy, the 95% adherence "threshold" is based on nucloside-exposed patients who are receiving partially suppressive, unboosted protease inhibitor regimens. Using unannounced pill counts and electronic medication monitoring, viral suppression is common with a 54%-100% mean adherence level to nonnucleoside reverse-transcriptase-inhibitor regimens. Although perfect adherence is an important goal, viral suppression is possible with moderate adherence to potent regimens.

UR - http://www.scopus.com/inward/record.url?scp=33748642352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748642352&partnerID=8YFLogxK

U2 - 10.1086/507526

DO - 10.1086/507526

M3 - Article

C2 - 16941380

AN - SCOPUS:33748642352

SN - 1058-4838

VL - 43

SP - 939

EP - 941

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 7

ER -

Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this